Patents by Inventor Timothy Duncan Owens

Timothy Duncan Owens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoproteasome inhibitors
    Patent number: 11827656
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • IMMUNOPROTEASOME INHIBITORS
    Publication number: 20230133165
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 14, 2018
    Publication date: May 4, 2023
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Immunoproteasome Inhibitors
    Publication number: 20220073538
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Applicant: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Immunoproteasome inhibitors
    Patent number: 11225493
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: January 18, 2022
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Immunoproteasome inhibitors
    Patent number: 11154563
    Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: October 26, 2021
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • IMMUNOPROTEASOME INHIBITORS
    Publication number: 20200277312
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 14, 2018
    Publication date: September 3, 2020
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • IMMUNOPROTEASOME INHIBITORS
    Publication number: 20190336515
    Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: January 16, 2018
    Publication date: November 7, 2019
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein